Request Demo
Arcturus Therapeutics to Attend Investor & Scientific Conferences - May 15, 2024
28 June 2024
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a renowned global messenger RNA (mRNA) medicines company, has announced its participation in several upcoming investor and scientific conferences. The company, headquartered in San Diego, California, is dedicated to crafting vaccines for infectious diseases and addressing rare liver and respiratory conditions.
Arcturus Therapeutics will be presenting at the TIDES USA: Oligonucleotide and Peptide Therapeutics conference on May 16, 2024, at 4:45 p.m. ET. This will be followed by a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024, at 2:30 p.m. ET. Another Fireside Chat will be held at the Piper Sandler Lung Investor Conference on May 23, 2024, at 2:30 p.m. ET. Lastly, the company will engage in a Fireside Chat at the Goldman Sachs 45th Annual Healthcare Conference on June 12, 2024, at 2:40 p.m. ET.
Founded in 2013, Arcturus is committed to advancing mRNA technology and has pioneered the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine, Kostaive®, which received approval. The company’s technologies include the LUNAR® lipid-mediated delivery system, STARR® mRNA Technology (sa-mRNA), and expertise in both mRNA drug substance and product manufacturing.
Arcturus has a significant global partnership with CSL Seqirus for innovative mRNA vaccines and a joint venture in Japan, ARCALIS, focusing on mRNA vaccine and therapeutic production. The company's research and development pipeline features RNA-based therapeutic candidates aimed at treating ornithine transcarbamylase deficiency and cystic fibrosis. Additionally, Arcturus is involved in developing mRNA vaccine programs targeting SARS-CoV-2 (COVID-19) and influenza.
The company's versatile RNA therapeutics platforms are applicable to various nucleic acid medicines, including mRNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technological advancements are protected by an extensive patent portfolio encompassing over 400 patents and patent applications across the U.S., Europe, Japan, China, and other regions.
Arcturus continues to be at the forefront of mRNA innovation, establishing itself as a pivotal player in the biotechnology landscape. The company's participation in these upcoming conferences underscores its commitment to advancing its cutting-edge technologies and fostering collaborations within the scientific and investment communities.
Arcturus Therapeutics will be presenting at the TIDES USA: Oligonucleotide and Peptide Therapeutics conference on May 16, 2024, at 4:45 p.m. ET. This will be followed by a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024, at 2:30 p.m. ET. Another Fireside Chat will be held at the Piper Sandler Lung Investor Conference on May 23, 2024, at 2:30 p.m. ET. Lastly, the company will engage in a Fireside Chat at the Goldman Sachs 45th Annual Healthcare Conference on June 12, 2024, at 2:40 p.m. ET.
Founded in 2013, Arcturus is committed to advancing mRNA technology and has pioneered the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine, Kostaive®, which received approval. The company’s technologies include the LUNAR® lipid-mediated delivery system, STARR® mRNA Technology (sa-mRNA), and expertise in both mRNA drug substance and product manufacturing.
Arcturus has a significant global partnership with CSL Seqirus for innovative mRNA vaccines and a joint venture in Japan, ARCALIS, focusing on mRNA vaccine and therapeutic production. The company's research and development pipeline features RNA-based therapeutic candidates aimed at treating ornithine transcarbamylase deficiency and cystic fibrosis. Additionally, Arcturus is involved in developing mRNA vaccine programs targeting SARS-CoV-2 (COVID-19) and influenza.
The company's versatile RNA therapeutics platforms are applicable to various nucleic acid medicines, including mRNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technological advancements are protected by an extensive patent portfolio encompassing over 400 patents and patent applications across the U.S., Europe, Japan, China, and other regions.
Arcturus continues to be at the forefront of mRNA innovation, establishing itself as a pivotal player in the biotechnology landscape. The company's participation in these upcoming conferences underscores its commitment to advancing its cutting-edge technologies and fostering collaborations within the scientific and investment communities.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.